Sponsor:
Kyverna Therapeutics
Code:
NCT06384976
Conditions
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis
MS
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
KYV-101
Standard lymphodepletion regimen
Anti-CD20 mAB
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations